Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
DJ Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
By Michael Dabaie
Oncolytics Biotech Inc. said it entered an at-the-market equity offering sales agreement with Canaccord Genuity LLC.
The agreement allows the company to issue common shares from treasury at prevailing market prices, with an aggregate gross sales amount of up to $80 million.
Oncolytics said the ATM facility provides it the option to tap into the financial markets as needed to support business development activities and clinical trials.
Oncolytics reported a net loss for the fourth quarter of C$9.3 million ($7.4 million), compared with a net loss of C$19.4 million in the fourth quarter of 2019. The loss per share was C$0.21 from C$0.71 in the prior-year period.
As of March 4, the company had about C$50 million in cash and cash equivalents.
The company said it is on track to report clinical biomarker and safety data in breast cancer this year.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 05, 2021 08:17 ET (13:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
DJ肿瘤学生物技术公司建立新的市场设施；第四季度亏损扩大
By Michael Dabaie
迈克尔·达拜(Michael Dabaie)著
Oncolytics Biotech Inc. said it entered an at-the-market equity offering sales agreement with Canaccord Genuity LLC.
Oncolytics Biotech Inc.说，它与Canaccel Genuity LLC达成了一项在市场上进行股权发行的销售协议。
The agreement allows the company to issue common shares from treasury at prevailing market prices, with an aggregate gross sales amount of up to $80 million.
该协议允许该公司以现行市场价格从国库发行普通股，总销售额高达8000万美元。
Oncolytics said the ATM facility provides it the option to tap into the financial markets as needed to support business development activities and clinical trials.
Oncolytics表示，自动取款机设施为其提供了根据需要进入金融市场的选择，以支持业务开发活动和临床试验。
Oncolytics reported a net loss for the fourth quarter of C$9.3 million ($7.4 million), compared with a net loss of C$19.4 million in the fourth quarter of 2019. The loss per share was C$0.21 from C$0.71 in the prior-year period.
Oncolytics报告第四季度净亏损930万加元(合740万美元)，而2019年第四季度净亏损1940万加元。每股亏损0.21加元，上年同期为0.71加元。
As of March 4, the company had about C$50 million in cash and cash equivalents.
截至3月4日，该公司拥有约5,000万加元的现金和现金等价物。
The company said it is on track to report clinical biomarker and safety data in breast cancer this year.
该公司表示，今年将报告乳腺癌的临床生物标记物和安全性数据。
Write to Michael Dabaie at michael.dabaie@wsj.com
写信给Michael Dabaie，电子邮件：michael.dabaie@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
March 05, 2021 08:17 ET (13:17 GMT)
2021年3月5日08：17美国东部时间(格林尼治标准时间13：17)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧